PhaseBio completes $49.5M stock sale
April 17, 2019 at 04:00 AM EDT
The Malvern company focused on orphan diseases plans to use the $39 million in net proceeds to advance its two lead new drug candidates.
Breaking News Bar
Business News and Information
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
| ||||||
bottom clear
